- 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
- 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
- 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
- 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
度洛西汀与帕罗西汀治疗伴有疼痛症状抑郁障碍效果分析
度洛西汀与帕罗西汀治疗伴有疼痛症状抑郁障碍效果分析
许德河1 汤义平2 陈英颖1 林雪菜1
1.浙江省台州巿第二人民医院药剂科,浙江台州 317200;
2.浙江省台州巿第二人民医院心身科,浙江台州 317200
[摘要] 目的 探讨度洛西汀与帕罗西汀治疗伴有疼痛症状抑郁障碍的临床效果及安全性。 方法 将116例伴有疼痛症状的抑郁障碍患者随机分为度洛西汀组与帕罗西汀组,每组各58例,度洛西汀组给予度洛西汀肠溶胶囊口服治疗,初始剂量:30~60 mg/d,可追加至90 mg/d。帕罗西汀组给予帕罗西汀片口服治疗,初始剂量:20 mg/d,可追加至50 mg/d。治疗8周后观察两组患者抑郁症状、疼痛症状及不良反应情况。 结果 两组治疗8周后HAMD评分均较治疗前有明显下降(P 0.05)。 结论 度洛西汀在治疗伴有疼痛症状的抑郁障碍方面具有起效快、疼痛改善明显、不良反应少等优点,可作为目前治疗伴有疼痛症状的抑郁障碍的首选方案。
[关键词] 抑郁障碍;疼痛;度洛西汀;帕罗西汀;不良反应
[中图分类号] R749 [文献标识码] A [文章编号] 1673-7210(2014)03(a)-0058-04
Efficacy analysis of Duloxetine and Paroxetine in the treatment of depressive disorder accompanied by pain
XU Dehe1 TANG Yiping2 CHEN Yingying1 LIN Xuecai1
1.Department of Pharmacy, Taizhou Second Peoples Hospital, Zhejiang Province, Taizhou 317200, China; 2.Psychosomatic Department, Taizhou Second Peoples Hospital, Zhejiang Province, Taizhou 317200, China
[Abstract] Objective To discuss the clinical effect and safety of Duloxetine and Paroxetine in the treatment of depressive disorder accompanied by pain. Methods 116 patients who suffered depressive disorder accompanied by pain were randomly divided into the Duloxetine group and Paroxetine group with 58 cases in each group. The Duloxetine group was treated by Duloxetine Enteric-coated Capsules orally; the initial dose stood at 30-60 mg/d and could be increased to 90 mg/d. And the Paroxetine group received the oral treatment of Paroxetine Tablets, whose dose was 20 mg/d initially and 50 mg/d at a minimum. Two groups were observed after 8 weeks of treatment in terms of depressive symptoms, pains and adverse reactions. Results After 8 weeks of treatment, HAMD scores in both groups were significantly decreased compared with before treatment (P 0.05). Conclusion Duloxetine can produce fast effects and achieve noticeable alleviation of pain while causing few adverse reactions in the treatment of depressive disorder accompanied by pain, qualifying itself as a chief choice in treating depressiv
文档评论(0)